Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3398-3405

  Dawson, Nancy A ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; HORMONE RESISTANCE; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; STANDARD; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0031726901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3398     Document Type: Article

References (27)

1. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the targe. J Natl Cancer Inst 88:1623-1634, 1996
2. Newling D, Fossa SD, Anderson L, et al: Assessment of hormone-refractory prostate cancer. Urology 49:46-53, 1997 (suppl 4A)
3. Scher HI Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 15:2928-2938, 1997
4. Figg WD, Ammerman K, Patronas N, et al: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest 14:513-517, 1996
5. Elkin M, Mueller HP: Metastases from cancer of the prostate. Cancer 7:602-610, 1954
6. Smith PH, Bono A, da Silva C, et al: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. Cancer 66:1009-1016, 1990
7. Pollen JJ, Witztum KF, Ashburn WL: The flare phenomenon on radionucleotide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 142:773-776, 1984
8. Dawson N, Wilding G, Weiss RB, et al: A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. Cancer 69:213-218, 1992
9. Eisenberger M, Blumenstein B, Scardino P, et al: Evaluation of chemotherapy in endocrine-resistant prostate cancer in patients with measurable versus bone disease only: The SWOG experience. Proc Am Soc Clin Oncol 9:153, 1990 (abstr)
10. Scher HI, Yagoda A, Ahmed T, et al: Methylglyoxal-bis(guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate. J Clin Oncol 3:224-228, 1985.
11. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
12. Kelly WK, Scher HI, Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
13. Smith DC, Dunn RL, Strawderman MS, et al: Changes in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16:1835-1843, 1998
14. Hall R, Hedlund PO, Ackermann R, et al: Evaluation and follow-up of patients with N1-3 MO or NXM1 prostate cancer in phase III trials. Urology 49:39-45, 1997 (suppl 4A)
15. Crawford ED, Stone NN, Garnick M, et al: Results of a national survey of urology practice patterns and patient experience from men with prostate cancer. J Urol 155:606A, 1996 (abstr)
16. Murphy GP, Slack NH: Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1:375-382, 1980
17. Akaza H, Jones WG, Javadpour N, et al: Objective response criteria in prostate cancer, in EORTC Genitourinary Group: Monograph 7: Prostate Cancer and Testicular Cancer. New York, NY, Wiley-Liss, 1990, pp 193-197
18. Newling DWW: Parameters of response and progression in prostate cancer, in EORTC Genitourinary Group: Monograph 8: Treatment of Prostatic Cancer - Facts and Controversies. New York, NY, Wiley-Liss, 1990, pp 25-48
19. Chisholm GD: Treatment of advanced prostate cancer. Semin Surg Oncol 1:38-55, 1985
20. World Health Organization Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979
21. Dawson NA, McLeod DG: The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints. Eur J Cancer 33:560-565, 1997
22. Dawson NA: Response criteria in prostatic carcinoma. Semin Oncol 1998 (in press)
23. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
24. Schroder FH, Norming U, Blumenstein BA, et al: Phase II studies in prostate cancer. Urology 49:3-14, 1997 (suppl 4A)
25. Goodman CM, Ritchie AWS, Chisholm GD: Measures of mortality in prostatic cancer. Br J Cancer 61:465-468, 1990
26. Waselenko JK, Dawson N: Emerging therapies for progressive metastatic prostate cancer. Oncology 11:1551-1560, 1997
27. Eisenberger MA, Simon R. O'Dwyer PJ, et al: A re-evaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985